Fresh off a funding round, Micropep discusses the promise of peptides for crop protection products
After closing a $40 million Series B, Micropep now looks to bring its crop protection products based on micropeptides to market.
After closing a $40 million Series B, Micropep now looks to bring its crop protection products based on micropeptides to market.
SOLASTA Bio says its biopeptide products perform “as effective or better than standard insecticides.”
Invaio and Peptyde Bio will be able to speed up development of and access to reliable, more sustainable crop protection.
The French startup is aiming to have its first biofungicide product on the market within the next three years.
“We have additional insecticide candidates at earlier stages in our pipeline, as well as our first fungicidal candidates,” CEO Anna Rath tells AFN.
The Series B funds will be used to scale up the Irish company’s platform, which aims to unlock additional health benefits for food and beverage products.
The Toulouse-based startup has developed technology that can enhance favorable genetic traits in crops without the need to tinker with their DNA.
Bovine mastitis is a major financial and welfare problem for dairy farmers, but standard antibiotic treatments are increasingly controversial.
Vestaron wants farmers to know that its peptide-based products are different from existing microbial products, offering more consistent efficacy with the same environmental benefits.
Plus: The “regenerative” versus “organic” debate rages on.
New funds will go towards commercializing Catalera products and building out the product development pipeline.
Expect fewer agtech-specific funds, more corporate involvement and lots of generative AI.
Widespread usage of GLP-1 drugs will have a profound impact on the food industry, predicts Wegovy user and founder of Sweden Foodtech Johan Jörgensen.
Challenges for the biologicals sector right now include dispelling a number of myths still prevalent in the industry.
Adapting to a changing environment while supporting growers is the over-arching theme of this year’s Salinas Biological Summit.
Bountica takes a novel approach to food preservation with proteins deployed by the immune system to fight off pathogens.
New consumer research from Mattson into users of GLP-1 drugs indicates they want more protein, smaller portion sizes, and foods that soothe nausea and digestive discomfort.
Time to hunker down, startups.
How will cultivated meat transition from a loss-making novelty served at a handful of restaurants to a viable alternative to animal ag?
Are GLP-1 drugs an ‘existential threat’ to the food industry or an opportunity for some creative thinking?